All In Biotech

NDA 016785 · Leadiant Biosci INC

Matulane

Procarbazine Hydrochloride · Oral

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1969

Jul 22, 1969

Approved uses

1

Original approval plus efficacy supplements

Registered trials

82

29 Phase 3, 5 recruiting

FAERS reports

4,792

1,270 serious, 323 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 9, 2026.

MATULANE is indicated for use in combination with other anticancer drugs for the treatment of Stage III or Stage IV Hodgkin Lymphoma. MATULANE is an alkylating drug indicated for use in combination with other anticancer drugs for the treatment of Stage III or Stage IV Hodgkin Lymphoma. ( 1 )

Mechanism: The precise mode of cytotoxic action of procarbazine has not been clearly defined. After metabolic activation, procarbazine may inhibit the transmethylation of methyl groups of methionine into transfer RNA (t-RNA). The unavailability of t-RNA prevents protein synthesis, and consequently prevents DNA and RNA synthesis. Procarbazine may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which directly damage DNA through an alkylation reaction.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 22, 1969 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
  • MATULANE · PROCARBAZINE HYDROCHLORIDE EQ 50MG BASE · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Procarbazine" as an intervention, any sponsor and status, largest first.

All 82 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea1,054
  • fatigue934
  • vomiting327
  • constipation296
  • platelet count decreased257
  • white blood cell count decreased244
  • headache198
  • decreased appetite194
  • rash173
  • diarrhoea147
  • neutropenia147
  • blood count abnormal132

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20047
20054
20062
20077
20085
20095
201045
2011136
2012250
201371
201455
2015201
2016245
2017592
2018555
2019348
2020318
2021233
2022355
2023344
2024358
2025345
2026311

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Matulane (Procarbazine HCl)

2024 spending

$1.9M

Beneficiaries

228

575 claims

Per beneficiary

$8,181

$130.54 per unit

View as table
YearSpending
2020$1,356,378
2021$1,319,228
2022$1,661,437
2023$1,679,771
2024$1,865,330

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 560 on PubMed

Sponsor: Leadiant Biosci INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.